MAPT and Alzheimer disease: Compared to the detection of the biomarkers in CSF, PET detection of AD biomarkers is a noninvasive method that assesses Aβ-amyloid and tau-protein distribution in the whole brain tissue and progression in dynamic in a longitudinal perspective, which would be beneficial for the prediction of clinical progression of disease and treatment assessment. Apart from the above, there are blood-based biomarkers for diagnosing AD, which have not yet been approved.